

# Sophoricoside

Catalog No: tcsc0008948



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

152-95-4

**Formula:**

$C_{21}H_{20}O_{10}$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 150$  mg/mL (346.92 mM)

**Observed Molecular Weight:**

432.38


## Product Description

Sophoricoside is an isoflavone glycoside isolated from *Sophora japonica* and has anti-inflammatory, anti-cancer and immunosuppressive effects.

***In Vitro:***

Sophoricoside is an isoflavone glycoside isolated from *Sophora japonica* and has anti-inflammatory, anti-cancer and immunosuppressive effects. The results show that Sophoricoside (50  $\mu\text{M}$ ) significantly inhibits the PMACI-induced histamine release. The inhibition rate reaches up to 30.24%. The maximal rates of TNF- $\alpha$ , IL-8 and IL-6 inhibition by Sophoricoside (50  $\mu\text{M}$ ) are approximately 31.42%, 43.43% and 34.24%, respectively. The rates of the levels of Rel/p65 inhibition in nuclear by Sophoricoside (50  $\mu\text{M}$ ) is approximately 50.14%. Results show that the enhanced caspase-1 activity induced by PMACI is significantly reduced by Sophoricoside in a dose-dependent manner<sup>[1]</sup>.

***In Vivo:*** When the Sophoricoside is orally administered 1 h before compound 48/80 injections, the scratching behaviors is reduced. The inhibition rate of Sophoricoside (2 mg/kg) is approximately 41.21%. Orally administered Sophoricoside inhibits the scratching behaviors by 47.31%. When mice are treated for 2 weeks with Sophoricoside, the atopic dermatitis is recovered to a significant extent<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!